214 related articles for article (PubMed ID: 30474946)
21. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
22. Rhenium-188-HEDP in the palliative treatment of bone metastases.
Liepe K; Hliscs R; Kropp J; Grüning T; Runge R; Koch R; Knapp FF; Franke WG
Cancer Biother Radiopharm; 2000 Jun; 15(3):261-5. PubMed ID: 10941533
[TBL] [Abstract][Full Text] [Related]
23. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):91-102. PubMed ID: 21068716
[TBL] [Abstract][Full Text] [Related]
24. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer.
Limouris G; Shukla SK; Manetou A; Kouvaris I; Plataniotis G; Triantafyllou N; Rigas AV; Vlahos L
Anticancer Res; 1997; 17(3B):1699-704. PubMed ID: 9179222
[TBL] [Abstract][Full Text] [Related]
25. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
Dafermou A; Colamussi P; Giganti M; Cittanti C; Bestagno M; Piffanelli A
Eur J Nucl Med; 2001 Jul; 28(7):788-98. PubMed ID: 11504074
[TBL] [Abstract][Full Text] [Related]
26. Application of rhenium-188 HEDP in bone metastases therapy.
Scheffler J; Derejko M; Bandurski T; Romanowicz G
Nucl Med Rev Cent East Eur; 2003; 6(1):55-7. PubMed ID: 14600935
[TBL] [Abstract][Full Text] [Related]
27. [Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)].
Holle LH; Humke U; Trampert L; Ziegler M; Kirsch CM; Oberhausen E
Urologe A; 1997 Nov; 36(6):540-7. PubMed ID: 9487590
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
[TBL] [Abstract][Full Text] [Related]
29. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
30. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
ter Heine R; Lange R; Breukels OB; Bloemendal HJ; Rummenie RG; Wakker AM; de Graaf H; Beekman FJ; van der Westerlaken MM; Malingré MM; Wielders JP; van den Berg L; Hendrikse NH; de Klerk JM
Int J Pharm; 2014 Apr; 465(1-2):317-24. PubMed ID: 24560635
[TBL] [Abstract][Full Text] [Related]
31. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
32. Palliative therapy with rhenium-186-HEDP for bone metastases of breast cancer.
Guerra UP; Englaro E; Cattaruzzi E
Tumori; 1997; 83(2):560-2. PubMed ID: 9226021
[No Abstract] [Full Text] [Related]
33. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
Han SH; de Klerk JM; Tan S; van het Schip AD; Derksen BH; van Dijk A; Kruitwagen CL; Blijham GH; van Rijk PP; Zonnenberg BA
J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552
[TBL] [Abstract][Full Text] [Related]
34. Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy.
Lambert B; de Klerk JM
Nucl Med Commun; 2006 Mar; 27(3):223-9. PubMed ID: 16479241
[TBL] [Abstract][Full Text] [Related]
35. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
[TBL] [Abstract][Full Text] [Related]
36. [Advanced prostate carcinoma: systemic radionuclide therapy of bone metastasis with rhenium-168-hydroxyethylidine diphosphonate].
Lerch H
Strahlenther Onkol; 1998 Jul; 174(7):384-5. PubMed ID: 9689963
[No Abstract] [Full Text] [Related]
37. The use of radioisotopes for palliation of metastatic bone pain.
Gkialas I; Iordanidou L; Galanakis I; Giannopoulos S
J BUON; 2008; 13(2):177-83. PubMed ID: 18555462
[TBL] [Abstract][Full Text] [Related]
38. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.
Bauman G; Charette M; Reid R; Sathya J
Radiother Oncol; 2005 Jun; 75(3):258-70. PubMed ID: 16299924
[TBL] [Abstract][Full Text] [Related]
39. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Liepe K; Runge R; Kotzerke J
J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
[TBL] [Abstract][Full Text] [Related]
40. Rhenium-188 HEDP to treat painful bone metastases.
Li S; Liu J; Zhang H; Tian M; Wang J; Zheng X
Clin Nucl Med; 2001 Nov; 26(11):919-22. PubMed ID: 11595844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
